1 Failure to respond |
2 |
215 |
Risk Ratio (M‐H, Random, 95% CI) |
0.99 [0.67, 1.47] |
1.1 TCAs versus BDZs |
1 |
61 |
Risk Ratio (M‐H, Random, 95% CI) |
1.03 [0.63, 1.67] |
1.2 SSRIs versus BDZs |
1 |
154 |
Risk Ratio (M‐H, Random, 95% CI) |
0.93 [0.48, 1.80] |
1.3 MAOIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
1.4 SNRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
1.5 NaSSAs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
1.6 NDRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
1.7 NRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
1.8 Other ADs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
2 Total number of dropouts |
7 |
1449 |
Risk Ratio (M‐H, Random, 95% CI) |
1.64 [1.03, 2.63] |
2.1 TCAs versus BDZs |
6 |
1295 |
Risk Ratio (M‐H, Random, 95% CI) |
1.67 [0.93, 2.99] |
2.2 SSRIs versus BDZs |
1 |
154 |
Risk Ratio (M‐H, Random, 95% CI) |
1.71 [1.03, 2.84] |
2.3 MAOIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
2.4 SNRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
2.5 NaSSAs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
2.6 NDRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
2.7 NRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
2.8 Other ADs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
3 Failure to remit |
3 |
1002 |
Risk Ratio (M‐H, Random, 95% CI) |
1.18 [1.01, 1.37] |
3.1 TCAs versus BDZs |
2 |
848 |
Risk Ratio (M‐H, Random, 95% CI) |
1.19 [1.00, 1.41] |
3.2 SSRIs versus BDZs |
1 |
154 |
Risk Ratio (M‐H, Random, 95% CI) |
1.12 [0.79, 1.59] |
3.3 MAOIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
3.4 SNRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
3.5 NaSSAs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
3.6 NDRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
3.7 NRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
3.8 Other ADs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
4 Panic symptoms ‐ endpoint score |
3 |
1144 |
Mean Difference (IV, Random, 95% CI) |
‐0.13 [‐1.06, 0.80] |
4.1 TCAs versus BDZs |
2 |
998 |
Mean Difference (IV, Random, 95% CI) |
‐0.25 [‐1.72, 1.22] |
4.2 SSRIs versus BDZs |
1 |
146 |
Mean Difference (IV, Random, 95% CI) |
0.10 [‐0.34, 0.54] |
4.3 MAOIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
4.4 SNRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
4.5 NaSSAs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
4.6 NDRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
4.7 NRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
4.8 Other ADs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5 Panic symptoms ‐ mean change |
1 |
44 |
Mean Difference (IV, Random, 95% CI) |
0.40 [‐0.83, 1.63] |
5.1 TCAs versus BDZs |
1 |
44 |
Mean Difference (IV, Random, 95% CI) |
0.40 [‐0.83, 1.63] |
5.2 SSRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5.3 MAOIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5.4 SNRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5.5 NaSSAs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5.6 NDRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5.7 NRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
5.8 Other ADs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
6 Frequency of panic attacks |
7 |
595 |
Mean Difference (IV, Random, 95% CI) |
0.33 [‐0.72, 1.38] |
6.1 TCAs versus BDZs |
6 |
458 |
Mean Difference (IV, Random, 95% CI) |
0.30 [‐0.81, 1.41] |
6.2 SSRIs versus BDZs |
1 |
137 |
Mean Difference (IV, Random, 95% CI) |
1.20 [‐3.31, 5.71] |
6.3 MAOIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
6.4 SNRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
6.5 NaSSAs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
6.6 NDRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
6.7 NRIs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
6.8 Other ADs versus BDZs |
0 |
0 |
Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
7 Agoraphobia |
5 |
1061 |
Std. Mean Difference (IV, Random, 95% CI) |
0.04 [‐0.08, 0.16] |
7.1 TCAs versus BDZs |
4 |
949 |
Std. Mean Difference (IV, Random, 95% CI) |
0.04 [‐0.08, 0.17] |
7.2 SSRIs versus BDZs |
1 |
112 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [‐0.37, 0.37] |
7.3 MAOIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
7.4 SNRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
7.5 NaSSAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
7.6 NDRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
7.7 NRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
7.8 Other ADs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
8 General anxiety |
8 |
1365 |
Std. Mean Difference (IV, Random, 95% CI) |
0.06 [‐0.25, 0.37] |
8.1 TCAs versus BDZs |
7 |
1238 |
Std. Mean Difference (IV, Random, 95% CI) |
0.08 [‐0.28, 0.45] |
8.2 SSRIs versus BDZs |
1 |
127 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.08 [‐0.42, 0.27] |
8.3 MAOIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
8.4 SNRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
8.5 NaSSAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
8.6 NDRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
8.7 NRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
8.8 Other ADs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
9 Depression |
6 |
892 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.14 [‐0.29, 0.02] |
9.1 TCAs versus BDZs |
5 |
765 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.08 [‐0.22, 0.06] |
9.2 SSRIs versus BDZs |
1 |
127 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.46 [‐0.81, ‐0.11] |
9.3 MAOIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
9.4 SNRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
9.5 NaSSAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
9.6 NDRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
9.7 NRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
9.8 Other ADs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
10 Social functioning |
4 |
1007 |
Std. Mean Difference (IV, Random, 95% CI) |
0.16 [‐0.12, 0.44] |
10.1 TCAs versus BDZs |
3 |
882 |
Std. Mean Difference (IV, Random, 95% CI) |
0.23 [0.03, 0.42] |
10.2 SSRIs versus BDZs |
1 |
125 |
Std. Mean Difference (IV, Random, 95% CI) |
‐0.22 [‐0.57, 0.13] |
10.3 MAOIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.4 SNRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.5 NaSSAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.6 NDRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.7 NRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
10.8 Other ADs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11 Quality of life |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.1 TCAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.2 SSRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.3 MAOIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.4 SNRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.5 NaSSAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.6 NDRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.7 NRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
11.8 Other ADs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12 Patient satisfaction |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.1 TCAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.2 SSRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.3 MAOIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.4 SNRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.5 NaSSAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.6 NDRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.7 NRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
12.8 Other ADs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13 Economic costs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.1 TCAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.2 SSRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.3 MAOIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.4 SNRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.5 NaSSAs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.6 NDRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.7 NRIs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
13.8 Other ADs versus BDZs |
0 |
0 |
Std. Mean Difference (IV, Random, 95% CI) |
0.0 [0.0, 0.0] |
14 Number of dropouts due to adverse effects |
3 |
1002 |
Risk Ratio (M‐H, Random, 95% CI) |
1.72 [1.03, 2.87] |
14.1 TCAs versus BDZs |
2 |
848 |
Risk Ratio (M‐H, Random, 95% CI) |
2.10 [1.13, 3.93] |
14.2 SSRIs versus BDZs |
1 |
154 |
Risk Ratio (M‐H, Random, 95% CI) |
1.2 [0.55, 2.61] |
14.3 MAOIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
14.4 SNRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
14.5 NaSSAs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
14.6 NDRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
14.7 NRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
14.8 Other ADs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
15 Number of patients experiencing at least one adverse effect |
1 |
154 |
Risk Ratio (M‐H, Random, 95% CI) |
1.03 [0.92, 1.15] |
15.1 TCAs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
15.2 SSRIs versus BDZs |
1 |
154 |
Risk Ratio (M‐H, Random, 95% CI) |
1.03 [0.92, 1.15] |
15.3 MAOIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
15.4 SNRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
15.5 NaSSAs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
15.6 NDRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
15.7 NRIs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |
15.8 Other ADs versus BDZs |
0 |
0 |
Risk Ratio (M‐H, Random, 95% CI) |
0.0 [0.0, 0.0] |